1302 — LifeTech Scientific Income Statement
0.000.00%
Last trade - 00:00
- HK$6.85bn
- HK$6.40bn
- CNY1.27bn
- 61
- 25
- 27
- 27
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 669 | 642 | 925 | 1,097 | 1,267 |
Cost of Revenue | |||||
Gross Profit | 535 | 513 | 748 | 874 | 996 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 480 | 378 | 597 | 729 | 884 |
Operating Profit | 189 | 264 | 329 | 368 | 383 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 171 | 243 | 333 | 378 | 176 |
Provision for Income Taxes | |||||
Net Income After Taxes | 127 | 207 | 283 | 319 | 107 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 129 | 216 | 292 | 325 | 263 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 129 | 216 | 292 | 325 | 263 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.031 | 0.048 | 0.063 | 0.076 | 0.059 |